Johnson & Johnson (JNJ) To Go Ex-Dividend on February 26th

Johnson & Johnson (NYSE:JNJ) declared a quarterly dividend on Tuesday, January 2nd, RTT News reports. Stockholders of record on Tuesday, February 27th will be paid a dividend of 0.84 per share on Tuesday, March 13th. This represents a $3.36 dividend on an annualized basis and a dividend yield of 2.55%. The ex-dividend date of this dividend is Monday, February 26th.

Johnson & Johnson has increased its dividend payment by an average of 6.4% per year over the last three years and has increased its dividend annually for the last 55 consecutive years. Johnson & Johnson has a dividend payout ratio of 46.2% meaning its dividend is sufficiently covered by earnings. Analysts expect Johnson & Johnson to earn $8.63 per share next year, which means the company should continue to be able to cover its $3.36 annual dividend with an expected future payout ratio of 38.9%.

Johnson & Johnson (NYSE JNJ) opened at $132.02 on Friday. The company has a market cap of $354,196.75, a price-to-earnings ratio of 18.08, a PEG ratio of 2.21 and a beta of 0.74. Johnson & Johnson has a 1-year low of $120.90 and a 1-year high of $148.32. The company has a debt-to-equity ratio of 0.51, a current ratio of 1.41 and a quick ratio of 1.02.

Johnson & Johnson (NYSE:JNJ) last announced its earnings results on Tuesday, January 23rd. The company reported $1.74 EPS for the quarter, beating analysts’ consensus estimates of $1.72 by $0.02. The business had revenue of $20.20 billion for the quarter, compared to analysts’ expectations of $20.08 billion. Johnson & Johnson had a net margin of 1.70% and a return on equity of 29.00%. The company’s quarterly revenue was up 11.5% on a year-over-year basis. During the same period in the previous year, the company posted $1.58 EPS. analysts predict that Johnson & Johnson will post 8.11 earnings per share for the current fiscal year.

Several equities analysts have issued reports on JNJ shares. Vetr raised shares of Johnson & Johnson from a “hold” rating to a “buy” rating and set a $150.89 price objective on the stock in a research note on Thursday, January 11th. Royal Bank of Canada reissued a “buy” rating on shares of Johnson & Johnson in a research note on Tuesday, January 9th. Credit Suisse Group set a $154.00 price objective on shares of Johnson & Johnson and gave the company a “hold” rating in a research note on Monday, January 22nd. Zacks Investment Research cut shares of Johnson & Johnson from a “buy” rating to a “hold” rating in a research note on Tuesday, December 12th. Finally, Stifel Nicolaus boosted their price objective on shares of Johnson & Johnson from $142.00 to $145.00 and gave the company a “hold” rating in a research note on Wednesday, January 24th. Four research analysts have rated the stock with a sell rating, eight have given a hold rating, nine have assigned a buy rating and one has issued a strong buy rating to the company. The company currently has an average rating of “Hold” and a consensus price target of $146.16.

In other Johnson & Johnson news, VP Paulus Stoffels sold 155,342 shares of the business’s stock in a transaction on Thursday, February 15th. The shares were sold at an average price of $129.86, for a total transaction of $20,172,712.12. Following the sale, the vice president now directly owns 357,906 shares in the company, valued at approximately $46,477,673.16. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. 0.19% of the stock is currently owned by insiders.

Several hedge funds and other institutional investors have recently modified their holdings of JNJ. Beach Investment Management LLC. boosted its position in shares of Johnson & Johnson by 1,256.6% during the 2nd quarter. Beach Investment Management LLC. now owns 286,648 shares of the company’s stock worth $37,921,000 after purchasing an additional 265,518 shares in the last quarter. Signature Financial Management Inc. boosted its position in shares of Johnson & Johnson by 17.3% in the 2nd quarter. Signature Financial Management Inc. now owns 13,336 shares of the company’s stock worth $1,758,000 after buying an additional 1,967 shares in the last quarter. United Asset Strategies Inc. boosted its position in shares of Johnson & Johnson by 3.6% in the 2nd quarter. United Asset Strategies Inc. now owns 5,468 shares of the company’s stock worth $723,000 after buying an additional 192 shares in the last quarter. Tortoise Investment Management LLC boosted its position in shares of Johnson & Johnson by 3.3% in the 2nd quarter. Tortoise Investment Management LLC now owns 4,349 shares of the company’s stock worth $575,000 after buying an additional 139 shares in the last quarter. Finally, Alpine Woods Capital Investors LLC boosted its position in shares of Johnson & Johnson by 1.6% in the 2nd quarter. Alpine Woods Capital Investors LLC now owns 134,022 shares of the company’s stock worth $17,730,000 after buying an additional 2,117 shares in the last quarter. Institutional investors own 65.58% of the company’s stock.

TRADEMARK VIOLATION WARNING: “Johnson & Johnson (JNJ) To Go Ex-Dividend on February 26th” was first reported by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are viewing this report on another website, it was copied illegally and republished in violation of United States and international copyright law. The correct version of this report can be viewed at https://www.dispatchtribunal.com/2018/02/25/johnson-johnson-jnj-to-go-ex-dividend-on-february-26th.html.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. It operates through three segments: Consumer, Pharmaceutical and Medical Devices. Its primary focus is products related to human health and well-being.

Dividend History for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply